Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank Disease ID
1 Acute myeloid leukemia 💬
[1] KIT 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
[1] KIT 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
3 Acute myeloid leukemia 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
4 Acute myeloid leukemia 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
5 Acute myeloid leukemia 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
6 Adherens junction 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
7 Adherens junction 💬
[1] FGFR1 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
8 Adherens junction 💬
[1] FGFR1 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
9 Adherens junction 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
10 Adipocytokine signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
11 Adipocytokine signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
12 Adipocytokine signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
13 Adrenergic signaling in cardiomyocytes 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
14 Adrenergic signaling in cardiomyocytes 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
15 AGE-RAGE signaling pathway in diabetic complications 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
16 Alanine, aspartate and glutamate metabolism 💬
[4] ABAT, ALDH5A1, GAD1, GAD2 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
17 Alanine, aspartate and glutamate metabolism 💬
[4] ABAT, ALDH5A1, GAD1, GAD2 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
18 Alanine, aspartate and glutamate metabolism 💬
[4] ABAT, ALDH5A1, GAD1, GAD2 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
19 Aldosterone synthesis and secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
20 Aldosterone synthesis and secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
21 Aldosterone synthesis and secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
22 Alzheimer disease 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
23 Alzheimer disease 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
24 Alzheimer disease 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
25 Alzheimer disease 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
26 AMPK signaling pathway 💬
[1] HMGCR 💬 Simvastatin 💬 Simvastatin [22]  6 , 13, 15, 34, 46, 49, 51, 57, 66, 79, 86, 89, 94, 158, 160, 162, 195, 223, 265, 298, 299, 310 💬
27 AMPK signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
28 AMPK signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
29 AMPK signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
30 Amyotrophic lateral sclerosis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
31 Amyotrophic lateral sclerosis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
32 Amyotrophic lateral sclerosis 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
33 Apelin signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
34 Apelin signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
35 Apelin signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
36 Arachidonic acid metabolism 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
37 Autophagy - animal 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
38 Autophagy - animal 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
39 Autophagy - animal 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
40 Autophagy - other 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
41 Autophagy - other 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
42 Autophagy - other 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
43 Axon guidance 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
44 Axon guidance 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
45 Axon guidance 💬
[2] ABL1, SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
46 Bacterial invasion of epithelial cells 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
47 beta-Alanine metabolism 💬
[3] ABAT, GAD1, GAD2 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
48 beta-Alanine metabolism 💬
[3] ABAT, GAD1, GAD2 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
49 beta-Alanine metabolism 💬
[3] ABAT, GAD1, GAD2 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
50 Bile secretion 💬
[1] HMGCR 💬 Simvastatin 💬 Simvastatin [22]  6 , 13, 15, 34, 46, 49, 51, 57, 66, 79, 86, 89, 94, 158, 160, 162, 195, 223, 265, 298, 299, 310 💬
51 Bladder cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
52 Bladder cancer 💬
[1] FGFR3 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
53 Bladder cancer 💬
[1] FGFR3 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
54 Bladder cancer 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
55 Bladder cancer 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
56 Breast cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
57 Breast cancer 💬
[2] FGFR1, FLT4 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
58 Breast cancer 💬
[2] FGFR1, FLT4 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
59 Breast cancer 💬
[1] KIT 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
60 Breast cancer 💬
[1] KIT 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
61 Breast cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
62 Breast cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
63 Breast cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
64 Butanoate metabolism 💬
[4] ABAT, ALDH5A1, GAD1, GAD2 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
65 Butanoate metabolism 💬
[4] ABAT, ALDH5A1, GAD1, GAD2 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
66 Butanoate metabolism 💬
[4] ABAT, ALDH5A1, GAD1, GAD2 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
67 C-type lectin receptor signaling pathway 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
68 C-type lectin receptor signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
69 Cadherin signaling 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
70 Cadherin signaling 💬
[5] FGFR1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
71 Cadherin signaling 💬
[5] FGFR1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
72 Cadherin signaling 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
73 Cadherin signaling 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
74 Calcium signaling pathway 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
75 Calcium signaling pathway 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
76 Calcium signaling pathway 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
77 Calcium signaling pathway 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
78 Calcium signaling pathway 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
79 Calcium signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
80 Calcium signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
81 Calcium signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
82 Calcium signaling pathway 💬
[1] HRH1 💬 Loratadine 💬 Loratadine [5] 13, 19, 46, 89, 98 💬
83 Calcium signaling pathway 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
84 Calcium signaling pathway 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
85 Calcium signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
86 cAMP signaling pathway 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
87 cAMP signaling pathway 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
88 cAMP signaling pathway 💬
[1] SSTR2 💬 Octreotide 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
89 cAMP signaling pathway 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
90 cAMP signaling pathway 💬
[1] SSTR2 💬 Octreotide pamoate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
91 cAMP signaling pathway 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
92 cAMP signaling pathway 💬
[1] SSTR2 💬 Octreotide hydrochloride 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
93 Cell cycle 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
94 Cell cycle 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
95 Cell cycle 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
96 Cellular senescence 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
97 Cellular senescence 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
98 Cellular senescence 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
99 Central carbon metabolism in cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
100 Central carbon metabolism in cancer 💬
[5] FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
101 Central carbon metabolism in cancer 💬
[5] FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
102 Central carbon metabolism in cancer 💬
[2] KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
103 Central carbon metabolism in cancer 💬
[2] KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
104 Central carbon metabolism in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
105 Central carbon metabolism in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
106 Central carbon metabolism in cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
107 cGMP-PKG signaling pathway 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
108 cGMP-PKG signaling pathway 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
109 Chemical carcinogenesis - DNA adducts 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
110 Chemical carcinogenesis - reactive oxygen species 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
111 Chemical carcinogenesis - reactive oxygen species 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
112 Chemical carcinogenesis - reactive oxygen species 💬
[2] ABL1, SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
113 Chemical carcinogenesis - reactive oxygen species 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
114 Chemical carcinogenesis - reactive oxygen species 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
115 Chemical carcinogenesis - receptor activation 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
116 Chemical carcinogenesis - receptor activation 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
117 Chemical carcinogenesis - receptor activation 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
118 Chemical carcinogenesis - receptor activation 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
119 Chemical carcinogenesis - receptor activation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
120 Chemical carcinogenesis - receptor activation 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
121 Chemical carcinogenesis - receptor activation 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
122 Chemical carcinogenesis - receptor activation 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
123 Chemokine signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
124 Choline metabolism in cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
125 Choline metabolism in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
126 Choline metabolism in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
127 Choline metabolism in cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
128 Choline metabolism in cancer 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
129 Choline metabolism in cancer 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
130 Choline metabolism in cancer 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
131 Choline metabolism in cancer 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
132 Chronic myeloid leukemia 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
133 Chronic myeloid leukemia 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
134 Chronic myeloid leukemia 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
135 Circadian entrainment 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
136 Circadian entrainment 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
137 Circadian entrainment 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
138 Colorectal cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
139 Colorectal cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
140 Colorectal cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
141 Colorectal cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
142 Coronavirus disease 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
143 Cortisol synthesis and secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
144 Cortisol synthesis and secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
145 Cortisol synthesis and secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
146 Cushing syndrome 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
147 Cushing syndrome 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
148 Cushing syndrome 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
149 Cushing syndrome 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
150 Diabetic cardiomyopathy 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
151 Diabetic cardiomyopathy 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
152 Diabetic cardiomyopathy 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
153 Efferocytosis 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
154 Endocytosis 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
155 Endocytosis 💬
[3] FGFR2, FGFR3, PDGFRA 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
156 Endocytosis 💬
[3] FGFR2, FGFR3, PDGFRA 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
157 Endocytosis 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
158 Endocytosis 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
159 Endocytosis 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
160 Endometrial cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
161 Epithelial cell signaling in Helicobacter pylori infection 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
162 Epithelial cell signaling in Helicobacter pylori infection 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
163 ErbB signaling pathway 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
164 ErbB signaling pathway 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
165 ErbB signaling pathway 💬
[2] ABL1, SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
166 ErbB signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
167 ErbB signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
168 ErbB signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
169 ErbB signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
170 Estrogen signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
171 Estrogen signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
172 Fluid shear stress and atherosclerosis 💬
[1] KDR 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
173 Fluid shear stress and atherosclerosis 💬
[1] KDR 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
174 Fluid shear stress and atherosclerosis 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
175 Fluid shear stress and atherosclerosis 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
176 Focal adhesion 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
177 Focal adhesion 💬
[5] FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
178 Focal adhesion 💬
[5] FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
179 Focal adhesion 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
180 Focal adhesion 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
181 Focal adhesion 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
182 Focal adhesion 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
183 FoxO signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
184 GABAergic synapse 💬
[3] ABAT, GAD1, GAD2 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
185 GABAergic synapse 💬
[3] ABAT, GAD1, GAD2 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
186 GABAergic synapse 💬
[3] ABAT, GAD1, GAD2 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
187 GABAergic synapse 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
188 Gap junction 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
189 Gap junction 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
190 Gap junction 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
191 Gap junction 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
192 Gap junction 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
193 Gap junction 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
194 Gastric acid secretion 💬
[1] SSTR2 💬 Octreotide 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
195 Gastric acid secretion 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
196 Gastric acid secretion 💬
[1] SSTR2 💬 Octreotide pamoate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
197 Gastric acid secretion 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
198 Gastric acid secretion 💬
[1] SSTR2 💬 Octreotide hydrochloride 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
199 Gastric cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
200 Gastric cancer 💬
[1] FGFR2 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
201 Gastric cancer 💬
[1] FGFR2 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
202 Gastric cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
203 Gastric cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
204 Gastric cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
205 Glioma 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
206 Glioma 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
207 Glioma 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
208 Glioma 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
209 Glioma 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
210 Glioma 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
211 Glioma 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
212 Glioma 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
213 GnRH secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
214 GnRH secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
215 GnRH secretion 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
216 GnRH signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
217 GnRH signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
218 Growth hormone synthesis, secretion and action 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
219 Growth hormone synthesis, secretion and action 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
220 Growth hormone synthesis, secretion and action 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
221 Growth hormone synthesis, secretion and action 💬
[1] SSTR2 💬 Octreotide 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
222 Growth hormone synthesis, secretion and action 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
223 Growth hormone synthesis, secretion and action 💬
[1] SSTR2 💬 Octreotide pamoate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
224 Growth hormone synthesis, secretion and action 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
225 Growth hormone synthesis, secretion and action 💬
[1] SSTR2 💬 Octreotide hydrochloride 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
226 Hematopoietic cell lineage 💬
[1] KIT 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
227 Hematopoietic cell lineage 💬
[1] KIT 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
228 Hepatitis B 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
229 Hepatitis C 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
230 Hepatocellular carcinoma 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
231 Hepatocellular carcinoma 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
232 Hepatocellular carcinoma 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
233 Hepatocellular carcinoma 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
234 Herpes simplex virus 1 infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
235 Herpes simplex virus 1 infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
236 Herpes simplex virus 1 infection 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
237 Herpes simplex virus 1 infection 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
238 HIF-1 signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
239 HIF-1 signaling pathway 💬
[1] FLT1 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
240 HIF-1 signaling pathway 💬
[1] FLT1 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
241 HIF-1 signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
242 HIF-1 signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
243 HIF-1 signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
244 HIF-1 signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
245 Hormone signaling 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
246 Hormone signaling 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
247 Hormone signaling 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
248 Hormone signaling 💬
[1] SSTR2 💬 Octreotide 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
249 Hormone signaling 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
250 Hormone signaling 💬
[1] SSTR2 💬 Octreotide pamoate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
251 Hormone signaling 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
252 Hormone signaling 💬
[1] SSTR2 💬 Octreotide hydrochloride 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
253 Human cytomegalovirus infection 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
254 Human cytomegalovirus infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
255 Human cytomegalovirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
256 Human cytomegalovirus infection 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
257 Human cytomegalovirus infection 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
258 Human cytomegalovirus infection 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
259 Human cytomegalovirus infection 💬
[1] PDGFRA 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
260 Human cytomegalovirus infection 💬
[1] PDGFRA 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
261 Human cytomegalovirus infection 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
262 Human cytomegalovirus infection 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
263 Human cytomegalovirus infection 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
264 Human immunodeficiency virus 1 infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
265 Human immunodeficiency virus 1 infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
266 Human immunodeficiency virus 1 infection 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
267 Human papillomavirus infection 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
268 Human papillomavirus infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
269 Human papillomavirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
270 Human papillomavirus infection 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
271 Human papillomavirus infection 💬
[1] PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
272 Human papillomavirus infection 💬
[1] PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
273 Human papillomavirus infection 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
274 Human papillomavirus infection 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
275 Huntington disease 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
276 Huntington disease 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
277 Huntington disease 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
278 IgSF CAM signaling 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
279 IgSF CAM signaling 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
280 IgSF CAM signaling 💬
[2] ABL1, SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
281 IgSF CAM signaling 💬
[2] FGFR1, KDR 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
282 IgSF CAM signaling 💬
[2] FGFR1, KDR 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
283 IL-17 signaling pathway 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
284 Inflammatory mediator regulation of TRP channels 💬
[1] HRH1 💬 Loratadine 💬 Loratadine [5] 13, 19, 46, 89, 98 💬
285 Inflammatory mediator regulation of TRP channels 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
286 Insulin resistance 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
287 Insulin resistance 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
288 Insulin resistance 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
289 Insulin signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
290 Insulin signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
291 Insulin signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
292 Integrated stress response (ISR) signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
293 Integrated stress response (ISR) signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
294 Integrated stress response (ISR) signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
295 Integrin signaling 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
296 Integrin signaling 💬
[5] FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
297 Integrin signaling 💬
[5] FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
298 Integrin signaling 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
299 Integrin signaling 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
300 Integrin signaling 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
301 Integrin signaling 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
302 Integrin signaling 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
303 Integrin signaling 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
304 Integrin signaling 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
305 JAK-STAT signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
306 JAK-STAT signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
307 JAK-STAT signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
308 JAK-STAT signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
309 JAK-STAT signaling pathway 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
310 JAK-STAT signaling pathway 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
311 JAK-STAT signaling pathway 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
312 JAK-STAT signaling pathway 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
313 Kaposi sarcoma-associated herpesvirus infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
314 Kaposi sarcoma-associated herpesvirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
315 Kaposi sarcoma-associated herpesvirus infection 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
316 Kaposi sarcoma-associated herpesvirus infection 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
317 Kaposi sarcoma-associated herpesvirus infection 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
318 Kaposi sarcoma-associated herpesvirus infection 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
319 Leishmaniasis 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
320 Lipid and atherosclerosis 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
321 Longevity regulating pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
322 Longevity regulating pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
323 Longevity regulating pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
324 Longevity regulating pathway - multiple species 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
325 Longevity regulating pathway - multiple species 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
326 Longevity regulating pathway - multiple species 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
327 Lysosome biogenesis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
328 Lysosome biogenesis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
329 Lysosome biogenesis 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
330 MAPK signaling pathway 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
331 MAPK signaling pathway 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
332 MAPK signaling pathway 💬
[3] CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
333 MAPK signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
334 MAPK signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
335 MAPK signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
336 MAPK signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
337 MAPK signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
338 MAPK signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
339 Melanogenesis 💬
[1] KIT 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
340 Melanogenesis 💬
[1] KIT 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
341 Melanoma 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
342 Melanoma 💬
[3] FGFR1, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
343 Melanoma 💬
[3] FGFR1, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
344 Melanoma 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
345 Melanoma 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
346 MicroRNAs in cancer 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
347 MicroRNAs in cancer 💬
[2] ABL1, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
348 MicroRNAs in cancer 💬
[2] ABL1, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
349 MicroRNAs in cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
350 MicroRNAs in cancer 💬
[3] FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
351 MicroRNAs in cancer 💬
[3] FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
352 MicroRNAs in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
353 MicroRNAs in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
354 MicroRNAs in cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
355 MicroRNAs in cancer 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
356 MicroRNAs in cancer 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
357 Mitophagy - animal 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
358 mTOR signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
359 mTOR signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
360 mTOR signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
361 Neuroactive ligand signaling 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
362 Neuroactive ligand signaling 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
363 Neuroactive ligand signaling 💬
[1] HRH1 💬 Loratadine 💬 Loratadine [5] 13, 19, 46, 89, 98 💬
364 Neuroactive ligand-receptor interaction 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
365 Neuroactive ligand-receptor interaction 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
366 Neuroactive ligand-receptor interaction 💬
[1] HRH1 💬 Loratadine 💬 Loratadine [5] 13, 19, 46, 89, 98 💬
367 Neuroactive ligand-receptor interaction 💬
[1] SSTR2 💬 Octreotide 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
368 Neuroactive ligand-receptor interaction 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
369 Neuroactive ligand-receptor interaction 💬
[1] SSTR2 💬 Octreotide pamoate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
370 Neuroactive ligand-receptor interaction 💬
[1] SSTR2 💬 Octreotide acetate 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
371 Neuroactive ligand-receptor interaction 💬
[1] SSTR2 💬 Octreotide hydrochloride 💬 Octreotide [8] 67, 75, 77, 84, 85, 89, 193, 227 💬
372 Neurotrophin signaling pathway 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
373 Neurotrophin signaling pathway 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
374 Neurotrophin signaling pathway 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
375 Neutrophil extracellular trap formation 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
376 Neutrophil extracellular trap formation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
377 Neutrophil extracellular trap formation 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
378 Neutrophil extracellular trap formation 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
379 NF-kappa B signaling pathway 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
380 Non-small cell lung cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
381 Ovarian steroidogenesis 💬
[1] CYP19A1 💬 Letrozole 💬 Letrozole [2] 81, 89 💬
382 Ovarian steroidogenesis 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
383 Oxytocin signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
384 Oxytocin signaling pathway 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
385 Oxytocin signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
386 Pancreatic cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
387 Pancreatic cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
388 Pancreatic cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
389 Pancreatic cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
390 Pancreatic cancer 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
391 Parathyroid hormone synthesis, secretion and action 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
392 Parathyroid hormone synthesis, secretion and action 💬
[1] FGFR1 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
393 Parathyroid hormone synthesis, secretion and action 💬
[1] FGFR1 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
394 Pathogenic Escherichia coli infection 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
395 Pathogenic Escherichia coli infection 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
396 Pathogenic Escherichia coli infection 💬
[2] ABL1, SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
397 Pathways in cancer 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
398 Pathways in cancer 💬
[3] ABL1, KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
399 Pathways in cancer 💬
[3] ABL1, KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
400 Pathways in cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
401 Pathways in cancer 💬
[6] FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
402 Pathways in cancer 💬
[6] FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
403 Pathways in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
404 Pathways in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
405 Pathways in cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
406 Pathways in cancer 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
407 Pathways in cancer 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
408 Pathways of neurodegeneration - multiple diseases 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
409 Pathways of neurodegeneration - multiple diseases 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
410 Pathways of neurodegeneration - multiple diseases 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
411 Pathways of neurodegeneration - multiple diseases 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
412 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
413 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
414 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
415 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
416 Phospholipase D signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
417 Phospholipase D signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
418 Phospholipase D signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
419 Phospholipase D signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
420 Phospholipase D signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
421 Phospholipase D signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
422 Phospholipase D signaling pathway 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
423 Phospholipase D signaling pathway 💬
[2] PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
424 PI3K-Akt signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
425 PI3K-Akt signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
426 PI3K-Akt signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
427 PI3K-Akt signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
428 PI3K-Akt signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
429 PI3K-Akt signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
430 PI3K-Akt signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
431 PI3K-Akt signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
432 PI3K-Akt signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
433 Platelet activation 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
434 Prolactin signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
435 Propanoate metabolism 💬
[1] ABAT 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
436 Propanoate metabolism 💬
[1] ABAT 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
437 Propanoate metabolism 💬
[1] ABAT 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
438 Prostate cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
439 Prostate cancer 💬
[4] FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
440 Prostate cancer 💬
[4] FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
441 Prostate cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
442 Prostate cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
443 Prostate cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
444 Prostate cancer 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
445 Prostate cancer 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
446 Proteoglycans in cancer 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
447 Proteoglycans in cancer 💬
[2] FGFR1, KDR 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
448 Proteoglycans in cancer 💬
[2] FGFR1, KDR 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
449 Proteoglycans in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
450 Proteoglycans in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
451 Proteoglycans in cancer 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
452 Proteoglycans in cancer 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
453 Proteoglycans in cancer 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
454 Rap1 signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
455 Rap1 signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
456 Rap1 signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
457 Rap1 signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
458 Rap1 signaling pathway 💬
[2] KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
459 Rap1 signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
460 Rap1 signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
461 Ras signaling pathway 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
462 Ras signaling pathway 💬
[3] ABL1, KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
463 Ras signaling pathway 💬
[3] ABL1, KIT, PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
464 Ras signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
465 Ras signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
466 Ras signaling pathway 💬
[8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
467 Ras signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
468 Regulation of actin cytoskeleton 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
469 Regulation of actin cytoskeleton 💬
[5] FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
470 Regulation of actin cytoskeleton 💬
[5] FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
471 Regulation of actin cytoskeleton 💬
[1] PDGFRA 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
472 Regulation of actin cytoskeleton 💬
[1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
473 Regulation of actin cytoskeleton 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
474 Regulation of lipolysis in adipocytes 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
475 Regulation of lipolysis in adipocytes 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
476 Regulation of lipolysis in adipocytes 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
477 Relaxin signaling pathway 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
478 Relaxin signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
479 Relaxin signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
480 Renal cell carcinoma 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
481 Renin secretion 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
482 Renin secretion 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
483 Retrograde endocannabinoid signaling 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
484 Rheumatoid arthritis 💬
[1] FLT1 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
485 Rheumatoid arthritis 💬
[1] FLT1 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
486 Rheumatoid arthritis 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
487 Salivary secretion 💬
[1] ADRB2 💬 Albuterol sulfate 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
488 Salivary secretion 💬
[1] ADRB2 💬 Albuterol 💬 Albuterol [9] 12, 13, 86, 89, 113, 231, 256, 299, 340 💬
489 Serotonergic synapse 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
490 Shigellosis 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
491 Shigellosis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
492 Shigellosis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
493 Shigellosis 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
494 Shigellosis 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
495 Signaling pathways regulating pluripotency of stem cells 💬
[3] FGFR1, FGFR2, FGFR3 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
496 Signaling pathways regulating pluripotency of stem cells 💬
[3] FGFR1, FGFR2, FGFR3 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
497 Small cell lung cancer 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
498 Spinocerebellar ataxia 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
499 Spinocerebellar ataxia 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
500 Spinocerebellar ataxia 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
501 Steroid hormone biosynthesis 💬
[1] CYP19A1 💬 Letrozole 💬 Letrozole [2] 81, 89 💬
502 Taurine and hypotaurine metabolism 💬
[2] GAD1, GAD2 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
503 Taurine and hypotaurine metabolism 💬
[2] GAD1, GAD2 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
504 Taurine and hypotaurine metabolism 💬
[2] GAD1, GAD2 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
505 Terpenoid backbone biosynthesis 💬
[1] HMGCR 💬 Simvastatin 💬 Simvastatin [22]  6 , 13, 15, 34, 46, 49, 51, 57, 66, 79, 86, 89, 94, 158, 160, 162, 195, 223, 265, 298, 299, 310 💬
506 Th17 cell differentiation 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
507 Th17 cell differentiation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
508 Th17 cell differentiation 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
509 Thermogenesis 💬
[1] FGFR1 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
510 Thermogenesis 💬
[1] FGFR1 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
511 Thermogenesis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
512 Thermogenesis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
513 Thermogenesis 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
514 Thyroid hormone signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
515 Thyroid hormone signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
516 Thyroid hormone signaling pathway 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
517 Thyroid hormone signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
518 Tight junction 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
519 TNF signaling pathway 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
520 Transcriptional misregulation in cancer 💬
[1] FLT1 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
521 Transcriptional misregulation in cancer 💬
[1] FLT1 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
522 Tuberculosis 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
523 Type I diabetes mellitus 💬
[2] GAD1, GAD2 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
524 Type I diabetes mellitus 💬
[2] GAD1, GAD2 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
525 Type I diabetes mellitus 💬
[2] GAD1, GAD2 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
526 Type II diabetes mellitus 💬
[1] CACNA1G 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
527 Type II diabetes mellitus 💬
[1] CACNA1G 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
528 Type II diabetes mellitus 💬
[1] CACNA1G 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
529 Type II diabetes mellitus 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
530 Type II diabetes mellitus 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
531 Type II diabetes mellitus 💬
[1] MTOR 💬 Temsirolimus 💬 Temsirolimus [4] 13, 34, 89, 331 💬
532 Valine, leucine and isoleucine degradation 💬
[1] ABAT 💬 Divalproex sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
533 Valine, leucine and isoleucine degradation 💬
[1] ABAT 💬 Valproic acid 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
534 Valine, leucine and isoleucine degradation 💬
[1] ABAT 💬 Valproate sodium 💬 Valproic acid [11]  3 ,  5 , 26, 34, 51, 65, 89, 90, 145, 222, 331 💬
535 VEGF signaling pathway 💬
[1] KDR 💬 Nintedanib esylate 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
536 VEGF signaling pathway 💬
[1] KDR 💬 Nintedanib 💬 Nintedanib [7] 51, 84, 85, 89, 227, 228, 331 💬
537 VEGF signaling pathway 💬
[1] PTGS2 💬 Celecoxib 💬 Celecoxib [14]  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
538 VEGF signaling pathway 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
539 VEGF signaling pathway 💬
[1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
540 Viral carcinogenesis 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
541 Viral myocarditis 💬
[1] ABL1 💬 Imatinib mesylate 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
542 Viral myocarditis 💬
[1] ABL1 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
543 Viral myocarditis 💬
[1] ABL1 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
544 Virion - Hepatitis viruses 💬
[1] EGFR 💬 Cetuximab 💬 Cetuximab [5] 34, 51, 86, 89, 331 💬
545 Yersinia infection 💬
[1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬